Why Solar Energy Stocks Plunged By 20% or More
Investors will need to brace for more downside in solar energy firms. On Thursday, the U.S. House passed a “big beautiful” Trump bill that cut clean energy subsidies.Markets did not expect the bill would end so many of the subsidies. Watch out for Emphase Energy (ENPH), which lost nearly 20% yesterday. NextEra Energy (NEE), AES (AES), First Solar (FSLR), Array Technologies (ARRY), and Sunrun (RUN) are among the solar energy stocks to beware of.The firms previously benefited from funding from the Biden Administration’s Inflation Reduction Act. They will now see grants for cutting air pollution and greenhouse gas emissions repealed.Investors should infer from the removal of the 30% federal tax credit for those who install solar rooftop solutions. It will hurt electric vehicle stocks since buyers expect to get subsidies and tax credits phased out. Rivian Automotive (RIVN) and Lucid Group (LCID) might pull back from here. However, this might depend on the rally in Tesla (TSLA) stock losing its momentum.Your TakeawayThe U.S. government needs to reduce its $36 trillion debt. It does not have the means to subsidize an industry that loses money. Conversely, the U.S. market will miss out on the cheapest energy source. Industries like the data center will need to rely on more expensive energy sources instead.For now, avoid investing in the solar energy sector.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


